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Abstract: Men who have sex with men and transgender women in the United States are at increased
risk for HIV and may benefit from pre-exposure prophylaxis (PrEP), a once-a-day pill to prevent HIV.
Due to stigma and discrimination, sexual and gender minority (SGM) populations are also at risk for
depression and anxiety. This scoping review sought to identify literature addressing relationships
between the PrEP care continuum, depression, and anxiety among SGM individuals and others at
high risk for HIV. We conducted a systematic review of four databases (i.e., PubMed, PsycInfo, Web
of Science, Google Scholar) and identified 692 unique articles that were screened for inclusion criteria,
with 51 articles meeting the final inclusion criteria. Data were extracted for key study criteria (e.g.,
geographic location, participant demographics, study design, main findings). Results suggest that
while depression and anxiety are not associated with PrEP awareness or willingness to use, they
can be barriers to seeking care and to PrEP adherence. However, empirical studies show that taking
PrEP is associated with reductions in anxiety. Findings suggest the need to implement mental health
screenings in PrEP clinical care. In addition, addressing systemic and structural issues that contribute
to mental health disorders, as well as PrEP-related barriers, is critical.
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1. Introduction
Within the United States (US), ~1.2 million individuals were living with HIV in
2019 [1]. In that year alone, 36,801 individuals in the US and dependent areas were
newly diagnosed with HIV [1]. Although the annual number of new HIV diagnoses has
decreased since 2015 [1], continued efforts are needed to scale up prevention efforts to
meet current federal goals to end the HIV epidemic [2]. The Center for Disease Control
and Prevention (CDC) has identified gay, bisexual, and other men who have sex with
men (MSM) and transgender persons as key populations for HIV prevention. Indeed,
MSM accounted for 65% of new diagnoses in 2019, while MSM who also inject drugs
accounted for an additional 4% [3]. Transgender persons accounted for 2% of the new HIV
diagnoses in 2019, with transgender women (TGW) accounting for the vast majority (93%)
of these [3]. This is likely an underestimate of prevalence because gender is sometimes
reported incorrectly or is unavailable, leading to a reliance on sex rather than gender in
reporting [4]. Approximately 14% of TGW are living with HIV, with greater rates amongst
Black and Hispanic populations [5].
Pre-exposure prophylaxis (PrEP) is a once-a-day medication that, when taken regularly,
reduces an individual’s risk of acquiring HIV by sex by 99% and by injection drug use
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by 74–84% [6–8]. Since initial approval by the US Food and Drug Administration (FDA)
in 2012 under the brand name Truvada® , PrEP has also become available as a second
formulation under the brand name Descovy® and in a generic form under the brand name
Truvada® [6,9]. In addition, data from a clinical trial of a long-acting injectable (LAI-PrEP)
have been published, though it has not received FDA approval as of September 2021 [10,11].
According to CDC guidelines, MSM who have a sexual partner living with HIV, have a
recent bacterial sexually transmitted infection (STI), have multiple sex partners, or have a
history of inconsistent or no condom use are potential candidates for PrEP [12]. These same
PrEP indicators, as well as engagement in commercial sex work, apply for heterosexual
men and women living in areas with high HIV prevalence [12]. Finally, for people who
inject drugs (PWID), having an injecting partner living with HIV or sharing injection
equipment is an indicator for PrEP [12].
The PrEP care continuum according to Nunn et al.’s conceptualization includes nine
steps which can be used to assess PrEP programs. These steps fall into three general
categories: (1) PrEP awareness, (2) PrEP uptake, and (3) PrEP adherence and retention [13].
PrEP awareness includes three steps: identifying individuals at high risk for HIV, increasing
risk awareness, and enhancing PrEP awareness among these individuals. PrEP uptake
includes four steps: facilitating PrEP access, linking to PrEP care, prescribing PrEP, and
initiating PrEP. Finally, PrEP adherence and retention includes two steps: adhering to PrEP
and retaining individuals in PrEP care [13].
Despite a strong safety profile and high efficacy for preventing HIV, uptake of PrEP
has been slow and uneven in the US [14,15]. In addition, among those who do initiate
PrEP, significant racial and ethnic disparities exist, with African American and Hispanic
individuals being much less likely to use PrEP than White individuals, despite their higher
HIV risk [16]. Multiple individual-level barriers to PrEP initiation and adherence have been
identified, including lack of PrEP awareness and knowledge, concerns about side effects,
lack of affirming healthcare providers, health concerns, concerns about PrEP’s potential
role in future HIV drug resistence, and concerns about affordability [17–19]. Another
important potential individual-level barrier to PrEP uptake and retention is mental health.
Sexual and gender minority (SGM) individuals—including MSM and TGW—are
at increased risk for mental health disorders, such as depression and anxiety, due to
experiences of stigma, prejudice, and discrimination [20]. The lifetime prevalence of
depression within the general US population is 20% [21], compared with 26% for gay and
bisexual men [22] and 51% for TGW [23]. Likewise, the lifetime prevalence of generalized
anxiety disorder within the general US population is 6% [24], while it is 10% for gay and
bisexual men [22] and 40% for TGW [23]. Given the prevalence of anxiety and depression in
these groups, the World Health Organization (WHO) recommends screening for depression
and other mental health conditions among those who test positive for HIV [25]. Recent
calls have echoed this recommendation, suggesting that mental health services ought to
be integrated into HIV prevention efforts as well [26,27]. In addition, some clinics, such
as those funded by the Ryan White Program, currently use screening tools as a part of
PrEP prescription.
Given the high prevalence of depression and anxiety among SGM and other populations at high risk for HIV, it is important to explore potential relationships between
mental health disorders and the PrEP care continuum [13]. However, it is unclear to what
extent research has been conducted on this topic. Thus, the present scoping review seeks
to (1) identify existing literature examining potential bidirectional relationships between
the PrEP care continuum and depression and anxiety, and (2) identify gaps in the existing
literature and areas for future research.
2. Materials and Methods
We followed Arksey and O’Malley’s guidelines [28] for conducting a scoping review,
adopting suggestions by Levac et al. [29] and Peters et al. [30] when feasible. The protocol
was developed a priori but not pre-registered. It is available upon request from the corre-
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sponding author. We followed five steps in conducting the scoping review: (1) identifying
the research question; (2) identifying relevant studies; (3) study selection; (4) charting the
data; and (5) collating, summarizing, and reporting the results [28].
Two of the authors (SM and SH) collaboratively developed the search strategy and
inclusion criteria. Key terms related to PrEP, anxiety, depression, and mental health were
used to search PubMed, PsycInfo, Web of Science, and Google Scholar. Detailed search
criteria are shown in Table 1. The final search was conducted on 27 August 2021. All
results from PubMed, PsycInfo, and Web of Science were screened, and the first 300 results
from Google Scholar were screened, as recommended for searches aimed at academic
literature [31]. The following inclusion criteria were used: (1) full text article written
in English, (2) conducted in US, (3) published in a peer-reviewed journal, (4) published
between January 2012 and July 2021, (5) described original qualitative or quantitative
research, (6) included participants on PrEP or PrEP candidates (i.e., individuals from
groups at high risk for HIV including MSM, transgender individuals, and PWID), and
(7) included measures of depression and/or anxiety (i.e., symptoms or clinical diagnoses) as
key study variables (e.g., independent variable, dependent variable, mediator, moderator,
inclusion criteria, or qualitative focus) in relation to the PrEP care continuum step(s). The
review was limited to articles written in English due to study team constraints. It was
limited to studies conducted in the United States because of the varying nature of HIV
epidemics and presentation of mental health disorders across geographic and cultural
settings. Finally, 2012 was selected as the beginning year for inclusion as that was the year
of PrEP’s initial approval in the US [6].
First, duplicate results were removed. To screen articles, the first author worked
collaboratively with a trained research assistant. The primary coder screened articles based
on title and abstract, removing studies that clearly did not meet inclusion criteria. The
secondary screener reviewed initial screening decisions in an unblinded fashion. The two
screeners met to discuss any discrepancies in screening and come to a resolution. Next,
the primary coder screened articles based on full text. The secondary coder reviewed all
excluded articles to ensure accuracy. For all included articles, references were searched
based on title to identify studies that were not found through the database searches. In
addition, articles that cited the included studies, as identified through the “cited by”
function in Google Scholar, were also searched based on title for possible inclusion.
To chart the data, the following were extracted from each article by the first author:
author(s), year of publication, study location(s), trial name when applicable, study design,
sample demographics, sampling strategy, study aims, mental health disorder(s) of focus,
tools/measures used to assess mental health, tools/measures used to assess PrEP outcomes,
main findings, and study limitations. The extracted variables are included in tables, with
the exception of trial name, sampling strategy, and study limitations. These data are
included in the narrative description of studies, when applicable.
To synthesize the findings, reviewed articles were then grouped by mental health disorder (i.e., depression and/or anxiety) and PrEP care continuum step (i.e., PrEP awareness,
PrEP uptake, and/or PrEP adherence and retention). The authors examined and discussed
the findings for each mental health disorder at each step of the PrEP care continuum.
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Table 1. Search Terms.
PubMed

PrEP

Anxiety

Depression

Mental
Health

Limiters

(Pre-Exposure Prophylaxis[Mesh] OR
“pre-exposure
prophylaxis”[Title/Abstract]
OR “preexposure
prophylaxis”[Title/Abstract]
OR “pre exposure prophylaxis”
[Title/Abstract]
OR PrEP [Title/Abstract]
OR “HIV PrEP” [Title/Abstract] OR
tenofovir [Title/Abstract]
OR truvada [Title/Abstract]
OR emtricitabine [Title/Abstract] OR
descovy [Title/Abstract])
AND

PsycInfo

Web of Science

Google Scholar

(DE(“Pre-Exposure Prophylaxis”) OR AB
(“pre-exposure prophylaxis” OR
“preexposure prophylaxis” OR “pre
exposure prophylaxis” OR PrEP OR “HIV
PrEP” OR tenofovir OR truvada OR
emtricitabine OR descovy) OR TI
(“pre-exposure prophylaxis” OR
“preexposure prophylaxis” OR “pre
exposure prophylaxis” OR PrEP OR “HIV
PrEP” OR tenofovir OR truvada OR
emtricitabine OR descovy))

(AB = (“pre-exposure prophylaxis” OR
“preexposure prophylaxis” OR “pre
exposure prophylaxis” OR PrEP OR “HIV
PrEP” OR tenofovir OR truvada OR
emtricitabine OR descovy) OR
TI = (“pre-exposure prophylaxis” OR
“preexposure prophylaxis” OR “pre
exposure prophylaxis” OR PrEP OR “HIV
PrEP” OR tenofovir OR truvada OR
emtricitabine OR descovy))

(PrEP OR “pre-exposure prophylaxis” OR
“pre exposure prophylaxis” OR
“preexposure prophylaxis” OR tenofovir
OR truvada OR descovy)

AND

“Anxiety”[Mesh] OR “Anxiety
Disorders”[Mesh] OR
anxiety[Title/Abstract] OR
anxious[Title/Abstract]

DE(“Anxiety” OR “Anxiety Disorders”
OR “Generalized Anxiety Disorder”) OR
AB(anxiety OR anxious) OR TI (anxiety
OR anxious)

OR

OR

(“Depression”[Mesh] OR “Depressive
Disorder”[Mesh] OR “Depressive
Disorder, Major”[Mesh] OR
depress*[Title/Abstract])

(DE (“Major Depression” OR
“Depression(Emotion)”) OR AB(depress *)
OR TI(depress *)

OR
(“Mental Health”[Mesh] OR “Mental
Disorders”[Mesh] OR “mental
health”[Title/Abstract] OR “mental
disorder”[Title/Abstract])
From: 2012/1/1
English
Article Type: Journal Article

OR
(DE (“Mental Health” OR “Mental
Disorders”) OR AB(“mental health” OR
“mental disorder”) OR TI (“mental health”
OR “mental disorder”))
Publication Year: 2012–2021
Source Types: Academic Journals

AND
AB = (“generalized anxiety disorder” OR
“anxiety disorder” OR anxiety OR
anxious) OR TI = (“generalized anxiety
disorder” OR “anxiety disorder” OR
anxiety OR anxious)
OR
(AB = (“major depression” OR
“depressive disorder” OR “major
depressive disorder” OR depress *) OR
TI = (“major depression” OR “depressive
disorder” OR “major depressive disorder”
OR depress *)
OR

AND

anxiety OR anxious

OR

depression OR depressive OR depress *

OR

(AB = (“mental health” OR “mental
disorder”) OR TI = (“mental health” OR
“mental disorder”))

(“mental health” OR “mental disorder”)

Language: (English)
Document Types (Article)
Timespan = 2012–2021

NA

Note: * indicates a truncated search technique yielding results for all terms which begin with the listed root.
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3. Results
Our search yielded 994 initial articles (436 PubMed, 85 PsycInfo, 173 Web of Science,
300 Google Scholar). A total of 302 duplicates were identified and removed, yielding
692 unique articles. After screening all titles/abstracts, an additional 573 were removed,
resulting in 119 articles that were included for full text screening. One article was not
available for full text review, and its corresponding author did not reply to a request to
share a full text version. Thus, 118 full text articles were screened. Of these, 45 were
Int. J. Environ. Res. Public Health 2021, 18, x FOR PEER REVIEW
5 of 27
identified for inclusion. Screening references and citations of these included
articles yielded
six additional articles that met the inclusion criteria. Therefore, a total of 51 articles are
included in this scoping review. See Figure 1 for a flow chart detailing this process.

Figure 1. PRISMA flow chart [32].
Figure
1. PRISMA flow chart [32].

4. Depression

4. Depression
4.1. PrEP Awareness
4.1. PrEP Awareness
Fifteen articles were identified that examined depression and PrEP awareness and/or
willingness
to use
PrEPidentified
(see Table 2).that
The examined
majority of these
studies found
depressive
Fifteen
articles
were
depression
andthat
PrEP
awareness and/or
symptoms
werePrEP
not correlated
with2).
PrEP
awareness
or willingness
to use PrEP.
willingness
to use
(see Table
The
majority
of these studies
found that depressive
Five studies that recruited MSM from major US cities found that a positive screening
symptoms
were not correlated with PrEP awareness or willingness to use PrEP.
for depressive symptoms was not associated with PrEP awareness [33-37] or reported
Five
studiestothat
MSM
from
major
US cities found
a positive
willingness
use recruited
[36]. This was
shown
through
cross-sectional
surveysthat
of 1274
Black screening
MSM across
the US [33]; was
374 MSM
Nashville, Tennessee
(TN) awareness
and Buffalo, New
York or reported
for depressive
symptoms
notinassociated
with PrEP
[33–37]
(NY) [36];
and 293
MSM
in Atlanta,
Georgia through
(GA) [37]; as
well as a serial cross-sectional
willingness
to use
[36].
This
was shown
cross-sectional
surveys of 1274 Black
survey of 2398 Black MSM [34]; and a repeated cross-sectional survey with 398 MSM at
MSM across
the US [33]; 374 MSM in Nashville, Tennessee (TN) and Buffalo, New York
time 1 and 558 MSM at time 2 [35]. Another cross-sectional study of 234 individuals who
(NY) [36];
and
293 MSM
in Atlanta,
[37]; between
as welldepressive
as a serial
cross-sectional
were dependent
on opioids
similarlyGeorgia
found no (GA)
relationship
sympsurveytoms
of 2398
Black
MSM [38].
[34]; and a repeated cross-sectional survey with 398 MSM at
and PrEP
awareness
studies at
found
no 2relationship
between
depressive symptoms
andofPrEP
time 1 andThree
558 MSM
time
[35]. Another
cross-sectional
study
234awareindividuals who
ness and interest in samples of women. A cross-sectional study with 232 female sex workwere dependent on opioids similarly found no relationship between depressive symptoms
ers found that depressive symptoms were not associated with PrEP awareness or interest
and PrEP
[38]. in New York City, NY, another cross-sectional study found that
[39].awareness
Among 190 women
Three
studies
no relationship
depressive
andstudy
PrEP awareness
depression
wasfound
not associated
with PrEPbetween
interest [40].
Finally, in symptoms
a cross-sectional
of 190 in
predominantly
American
women, depression
related
to willingand interest
samples of African
women.
A cross-sectional
study was
withnot
232
female
sex workers found
ness to use PrEP [41].
that depressive
symptoms were not associated with PrEP awareness or interest [39]. Among
190 women in New York City, NY, another cross-sectional study found that depression was
not associated with PrEP interest [40]. Finally, in a cross-sectional study of 190 predominantly
African American women, depression was not related to willingness to use PrEP [41].
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Table 2. Depression and PrEP Awareness.
Authors & Year

Location(s)

Sample Demographics

Design

Depression Measure
(Scoring)

Depression Related
Findings

Blashill, Brady, Rooney
et al. 2020 [42]

San Diego, CA

151 Latino MSM; mean age: 24.

Cross-sectional survey

PHQ-8
(10+ screened positive)

A psychosocial syndemic
(depression, binge drinking,
marijuana use, illicit
polysubstance use, childhood
sexual abuse) was not
associated with PrEP
awareness or willingness to
use.

Blackstock, Platt,
Golub et al. 2021 [40]

East Harlem, NY;
Bronx, NY

52 women,
11.5% TGW; 34.6% non-Latina Black;
51.9% Latina/Hispanic, 42.3% LGB;
mean age: 45.

Pilot test

PHQ-2
(dichotomous screening)

Depression was not
associated with PrEP interest.

Bologna, Panesar-Aguilar,
McCraney, and Cale 2020
[41]

United States

190 female individuals; 90% African
American; mean age: 22.

Cross-sectional survey

PHQ-9
(continuous)

Depression was not related to
willingness to use PrEP.

1274 Black MSM and TGW;
96% Male; 76% gay/same gender
loving; mean age: 30.

Cross-sectional survey

CESD-10
(10+ screened positive)

Depression not associated
with PrEP awareness.

2398 Black MSM, 82% MSM only;
3.4% Hispanic/Latino; mean age: 29.

Serial cross-sectional
survey

CESD-10
(10+ screened positive)

Depressive symptoms was
not associated with PrEP
awareness.

United States

398 MSM 2 months prior to iPrEX
trial results publication; 82% White;
89% Gay; mean age: 40. 558 MSM
2 months following publication;
84% White; 83% gay; mean age: 39.

Repeated cross-sectional
survey

CESD-10
(10+ screened positive)

Depression was not
associated with PrEP
awareness.

Kuo, Olsen, Patrick et al.
2016 [43]

Washington, DC

304 PWID; 69% male; 97.7% Black;
83% 50+ yrs.

Cross-sectional survey

CESD-10
(dichotomous screening)

Liu, Brown, Przybyla et al.
2021 [36]

Nashville, TN; Buffalo, NY

374 MSM, 60.2% Black; 77%
gay/homosexual; median age: 26.

Cross-sectional survey

PHQ-9
Categorical (0–4, 5–9, 10–14,
15–19, 20–27)

Eaton, Matthews,
Driffin et al. 2017 [33]
Friedman, Sang,
Bukowski et al. 2019 [34]

Krakower, Mimiaga,
Rosenberger et al. 2012
[35]

Atlanta, GA; Detroit, MI;
Houston, TX; Philadelphia,
PA; Washington DC
Atlanta, GA; Detroit, MI;
Houston, TX; Memphis, TN;
Philadelphia, PA; Washington
DC

Those who screened positive
for depressive symptoms
were more likely to be willing
to use PrEP.
Depression was not
associated with PrEP
awareness or willingness to
use.
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Table 2. Cont.
Authors & Year

Location(s)

Sample Demographics

Design

Depression Measure
(Scoring)

Ni, Altice,
Wickersham et al. 2021
[38]

Connecticut

234 individuals dependent on
opioids; 51% male; 63.3%
non-Hispanic White; mean age: 42.7.

Cross-sectional survey

CESD-20
(16+ screened positive)

Ojikutu, Bogart,
Higgins-Biddle et al. 2018
[44]

United States

855 participants; 54% female;
91% Black; 4% Latino.

Cross-sectional survey

Whooley et al. 1997 2-item
measure (categorical
frequency)

Shrestha, DiDomizio,
Kim et al. 2020 [45]

New Haven, CT

Cross-sectional survey

CESD
(16+ screened positive)

Shrestha, Karki,
Altice et al. 2017 [46]

New Haven, CT

Cross-sectional survey

CESD-20
(16+ screened positive)

Sullivan and Eaton 2020
[37]

Atlanta, GA

Cross-sectional survey

CESD-10
(10+ screened positive)

Tomko, Park, Allen et al.
2019 [39]

Baltimore, MD

Cross-sectional survey

CESD-10
(10+ screened positive)

Willie, Kershaw,
Blackstock et al. 2020 [47]

New Haven, CT; Bridgeport,
CT;
Hartfort, CT

Cross-sectional survey

PHQ-9
(10+ screened positive)

234 people who use drugs; 51% male;
63% White; 79% heterosexual;
mean age: 42.7.
400 people who use drugs; 58% male;
63% White; 15% Hispanic/Latino;
86% straight;
mean age: 41.
293 Black MSM;
56% gay/homosexual;
mean age: 30.
232 female sex workers;
66% non-Hispanic White;
50% ages < 35.
271 women; 36% non-Hispanic
White, 35% non-Hispanic Black;
28% Hispanic; 75% heterosexual;
61% ages 25+.

Note: PHQ = Patient Health Questionnaire, CESD = Center for Epidemiological Studies – Depression.

Depression Related
Findings
Moderate to severe
depression was not correlated
with willingness to use PrEP.
Depressive symptoms was
associated with greater PrEP
willingness amongst the
entire sample, but not
amongst those who were
PrEP indicated.
Depression was not
associated with willingness to
use LAI-PrEP.
Those who had moderate to
severe depression were more
likely to be willing to initiate
PrEP.
Depression was not
associated with PrEP
awareness.
Depressive symptoms were
not associated with PrEP
awareness or interest.
Adjusting for
sociodemographic variables,
there was no difference
between number of syndemic
conditions (IPV, depression,
substance use) and PrEP
interest or intentions to use.
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Two cross-sectional studies examined depression as a part of syndemic conditions,
finding no difference in PrEP interest between those with and without syndemic conditions. One study found that among 271 women at risk for HIV, having syndemic factors,
including depression, alcohol consumption, illicit drug use, or transactional sex was not
associated with lower likelihood of PrEP interest or intentions to use when controlling
for sociodemographic variables [47]. Similarly, a study conducted with 151 Latino gay,
bisexual, and other MSM in San Diego, California (CA) found that syndemic conditions, including depression, binge drinking, marijuana use, illicit polysubstance use, and childhood
sexual abuse, were not associated with PrEP awareness or willingness to use [33].
Cross-sectional studies involving people who use drugs yielded differential results
for the daily PrEP pill compared with LAI-PrEP. In a study conducted in Washington
DC, among 304 predominantly Black PWID, those who screened positive for depressive
symptoms were more likely to be willing to use PrEP compared with those who did not
screen positive for depressive symptoms [39]. Likewise, in a sample of 400 individuals
enrolled in a methadone program in New Haven, Connecticut (CT), those with moderate
to severe depression were more likely to be willing to use PrEP compared with those with
no to mild depression [46]. However, in a study involving 234 individuals enrolled in a
methadone program in New Haven, CT, depression was not correlated with willingness to
use LAI-PrEP [45].
A final study examined willingness to use PrEP amongst a predominantly Black
study population of 855 participants from the US. Within the entire sample, depressive
symptoms were associated with greater willingness to use PrEP. However, when the sample
was limited to those who had clear PrEP indications according to CDC guidelines, this
relationship disappeared [44].
4.2. PrEP Uptake
A total of 23 articles were identified that evaluated depression and outcomes of PrEP
access, uptake, and/or actual use (see Table 3).
PrEP Access. Three qualitative studies were identified that found depression to be a
barrier to PrEP access. A study conducted in southern CA with 30 TGW found that mental
health concerns were identified as barriers to PrEP care [48]. Similarly, another study
conducted in southern CA with 37 individuals, the majority of whom were transgender,
identified that mental disorder symptoms made PrEP access difficult [49]. Similarly, in a
study of 25 PrEP users in San Francisco, CA, one participant identified depression-related
and HIV-related stigma as a barrier to seeking care [50].
Linking to PrEP Care. Three studies were identified which examined components
of linking individuals to PrEP care. First, in a cross-sectional study conducted in CT
with 125 women involved in the criminal justice system, depressive symptoms were not
associated with PrEP eligibility as measured by CDC criteria [51]. Second, in a retrospective
chart review of 2995 PrEP candidates in southern California, depression according to
diagnostic codes in medical charts was not associated with PrEP referral [52]. Finally, in a
study with 52 women in New York City, depression was not correlated with acceptance of
an appointment to discuss PrEP [40].
PrEP Initiation. Seventeen additional articles detailed findings on depression and
PrEP initiation and/or use. Four of these studies examined PrEP initiation based on
depressive symptoms and found no relationship. In a longitudinal analysis of 154 Black
MSM in Atlanta, GA, depression was not associated with a delay between receiving a PrEP
prescription and initiating PrEP [53]. Similarly, in a prospective observational cohort study
with 298 non-Hispanic Black cisgender MSM in Atlanta, GA, depressive symptoms were
not associated with PrEP uptake as defined by the date of taking the first PrEP dose after
prescription [54]. Likewise, in two studies that examined a sample of 226 predominantly
Black MSM in Los Angeles, CA, Washington DC and Chapel Hill, North Carolina (NC),
there was no relationship between depressive symptoms and PrEP initiation as defined as
self-reported first date of taking PrEP [55,56].
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Table 3. Depression and PrEP Uptake.
Authors & Year

Location(s)

Sample Demographics

Depression Measure

Depression Related Findings

Cross-sectional survey

PHQ-8
10+ screened positive

A psychosocial syndemic
(depression, binge drinking,
marijuana use, illicit polysubstance
use, childhood sexual abuse) was not
associated with PrEP use.

Pilot test

PHQ-2
(dichotomous screening)

Depression was not associated with
PrEP appointment acceptance.

Retrospective Chart
Review

Diagnostic codes

Depression was not associated with
PrEP referral.
In bivariate analyses, depressive
symptoms were associated with
PrEP use. The association did not
hold in multivariable analyses.

Blashill, Brady,
Rooney et al. 2020 [42]

San Diego, CA

Blackstock, Platt,
Golub et al. 2021 [40]

East Harlem, NY; Bronx,
NY

Bruxvoort, Schumacher,
Towner et al. 2021 [52]

Southern California

Eaton, Matthews,
Driffin et al. 2017 [36]

Atlanta, GA; Detroit, MI;
Houston, TX; Philadelphia,
PA; Washington DC

1274 Black MSM and TGW;
96% male; 76% gay/same gender
loving; mean age: 30.

Cross-sectional survey

CESD-10
(10+ screened positive)

Friedman, Sang,
Bukowski et al. 2019 [34]

Atlanta, GA; Detroit, MI;
Houston, TX; Memphis, TN;
Philadelphia, PA;
Washington DC

2398 Black MSM, 82% MSMO;
3.4% Hispanic/Latino;
mean age: 29.

Serial cross-sectional
survey

CESD-10
(10+ screened positive)

Depressive symptoms were not
associated with PrEP use.

Repeated cross-sectional
survey

CESD-10
(10+ screened positive)

Depression was not associated with
PrEP use.

Qualitative Interviews

Qualitative focus

One participant reported stigma
surrounding depression and HIV
making it difficult to seek help.

Cross-sectional survey

PHQ-9
(categorical: 0–4, 5–9,
10–14, 15–19, 20–27)

Depression was not associated with
PrEP use.

Krakower, Mimiaga,
Rosenberger et al. 2012
[35]

United States

Laborde, Kinley,
Spinelli et al. 2020 [50]

San Francisco, CA

Liu, Brown, Przybyla et al.
2021 [36]

Nashville, TN; Buffalo, NY

151 Latino MSM men;
mean age: 24.

Design

52 women, 11.5% TGW;
34.6% non-Latina Black;
51.9% Latina/Hispanic, 42.3% LGB;
mean age: 45.
2995 PrEP candidates; 96.6% male;
60% racial/ethnic minorities;
age: 50% < 35.

398 MSM 2 months prior to iPrEX
publication; 82% White; 89% gay;
mean age: 40. 558 MSM 2 months
following publication; 84% White;
83% gay; mean age: 39.
25 current or former PrEP users;
60% MSM, 20% TGW who have sex
with men; 32% Black; 28%
Hispanic; ages 18–57.
374 MSM, 60.2% Black;
77% gay/homosexual;
median age: 26.
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Table 3. Cont.
Authors & Year

Sullivan and Eaton 2020
[37]

Location(s)

Atlanta, GA

Ni, Altice,
Wickersham et al. 2021
[38]

Connecticut

Ogunbajo, Storholm,
Ober et al. 2021 [48]

Southern California

Okafor, Hucks-Ortiz,
Hightow-Weidman et al.
2020 [56]
Serota, Rosenberg,
Thorne, Sullivan, and
Kelley 2019 [53]

Sample Demographics

293 Black MSM;
56% gay/homosexual;
mean age: 30

234 individuals dependent on
opioids; 51% male;
63.3% non-Hispanic White;
mean age: 42.7.
30 TGW; 33.3% Black/African
American;
53% Hispanic/Latina/Latinx;
46% straight/heterosexual;
mean age: 30.

Design

Depression Measure

Depression Related Findings

Cross-sectional survey

CESD-10
(10+ screened positive)

Depression alone was not associated
with PrEP use. However, having two
or more syndemic conditions
(depression symptoms, alcohol
consumption, illicit drug use,
transactional sex) was associated
with less likelihood of PrEP use.

Cross-sectional survey

CESD-20
(16+ screened positive)

Moderate to severe depression was
not correlated with PrEP use.

Mixed methods

Qualitative focus

Mental health concerns were a
barrier to PrEP uptake.

Los Angeles, CA;
Washington DC; Chapel
Hill, NC.

226 Black MSM; 60% > 25 yrs old.

Non-randomized
open-label PrEP study

CESD
(10+ screened positive)

No differences were found in PrEP
initiation by depression.

Atlanta, GA

154 Black MSM, 45% age 22–25.

Longitudinal

PHQ-8
(10+ screened positive)

Depression was not associated with a
delay between PrEP prescription and
initiation.

Atlanta, GA

298 non-Hispanic Black cis-gender
MSM; 73% gay; 62% ages 18–21.

Prospective
Observational Cohort
Study

PHQ-8
(10+ screened positive)

Depressive symptoms were not
associated with PrEP uptake.

Sewell, Powell,
Mayer et al. 2020 [57]

United States

9697 individuals; 92% male;
69% non-Hispanic White; mean
age: 43.

Cross-sectional survey

CESD
(continuous)

Those who used nondaily PrEP
compared with daily PrEP were
more likely to have higher
depressive symptoms.

Rutledge, Madden,
Ogbuagu, and Meyer
2018 [51]

Connecticut

125 women involved in the
criminal justice system; 69% White;
mean age: 37.

Cross-sectional survey

Unspecified

There was no difference in PrEP
eligibility by depressive symptoms.

Serota, Rosenberg,
Sullivan et al. 2020 [54]
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Table 3. Cont.
Authors & Year

Location(s)

Sample Demographics

Watson, Pasipanodya,
Savin et al. 2020 [49]

San Diego, CA; Los
Angeles, CA

37 individuals; 48% TGW,
27% trans men; 41% White,
non-Hispanic;
16% Latinx/Hispanic.

Wheeler, Fields,
Beauchamp et al. 2019
[55]

Los Angeles, CA;
Washington DC; Chapel
Hill, NC.

226 MSM; 86% Black; 73% gay;
median age: 26

Wood, Morales,
Metzger et al. 2020 [58]

Philadelphia, PA

Carneiro, Westmoreland,
Patel, and Grov 2020 [59]

United States

Chandler, Bukowski,
Matthews et al. 2020 [60]

Atlanta, GA; Detroit, MI;
Houston, TX; Memphis, TN;
Philadelphia, PA;
Washington DC

Eaton, Matthews,
Bukowski et al. 2018 [61]

Moeller, Seehuus, Wahl,
and Gratch 2020 [62]

Depression Measure

Depression Related Findings

Qualitative focus groups

Qualitative focus

Mental health concerns, including
depression and anxiety made it
difficult to access PrEP care as well
as other services.

Non-randomized
open-label PrEP study

CESD-10
(10+ screened positive)

Depressive symptoms were not
related to PrEP initiation.

Cross-sectional survey

PHQ-8
(10+ screened positive)

Cross-sectional survey

PHQ-4
(dichotomous screening)

1411 Black MSM;
80% gay/homosexual,
16% bisexual; 64% 18–29 years old

Cross-sectional survey

CESD-10
(10+ screened positive)

Philadelphia, PA; Detroit,
MI; Washington, DC;
Atlanta, GA; Houston, TX;
and Memphis, TN.

4184 Black MSM or TGW.
77.7% gay/same gender loving,
mean age: 30.47.

Cross-sectional survey

CESD-10
(10+ screened positive)

Depression was associated with
current PrEP use.

United States

2406 MSM; 55% White;
18.6% Latino; 78.6% gay;
mean age: 34.

Cross-sectional survey

PHQ-9
(categorical: 0–4, 5–9,
10–14, 15–19, 20+)

PrEP users reported lowest levels of
depression compared with non-PrEP
using participants. Use of PrEP was
not associated with depression.

247 individuals; 89% cis male;
46% African American; 19% Latinx
ethnicity; 47% ages 25–34.
6283 individuals; 98% cis men;
52% White; 33% 30–39 years old

Design

No associations were found between
depressive symptoms and mental
health treatment on PrEP use.
Depression was not associated with
PrEP use
There was no difference between
PrEP users and non-users in
depressive symptoms. In
considering syndemic psychosocial
conditions (substance use, intimate
partner violence, depression), those
with greater number of syndemic
conditions were more likely to report
PrEP use.
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Thirteen studies examined differences in depressive symptoms between PrEP users
and non-users in cross-sectional analyses with somewhat inconsistent findings. Three
studies with MSM found no association between depression and PrEP use [34–36]. This
was shown in a serial cross-sectional survey design with 2398 Black MSM [34], a repeated cross-sectional survey design with 398 MSM at time 1 and 558 MSM at time 2 [35],
and a cross-sectional design with 374 MSM [36]. Similarly, in a cross-sectional study of
6283 predominantly cisgender men that did not report sexual identity or behaviors, depressive symptoms were not correlated with PrEP use [59]. In a cross-sectional study of
247 predominantly cisgender males from Philadelphia, Pennsylvania (PA), there was no
relationship between depressive symptoms and self-reported PrEP use [58]. Likewise,
in a cross-sectional study conducted with 234 individuals dependent on opioids, moderate to severe depression was not correlated with PrEP use [38]. However, some studies
have found a relationship between depression and PrEP use. In a cross-sectional survey
of 2406 MSM in the US, PrEP users reported lower levels of depression than non-PrEP
users. However, in regression analyses, use of PrEP did not predict depression [62]. In a
cross-sectional survey of 4184 Black MSM and TGW, higher depressive symptoms were
associated with a greater likelihood of being a current PrEP user compared with non-PrEP
users [61]. Likewise, another cross-sectional study of 1274 Black MSM and TGW showed
via bivariate analyses that depressive symptoms were positively associated with PrEP
use [33]. However, this association disappeared when depressive symptoms were included
as a part of multivariable analyses [33].
In a cross-sectional survey of 1411 Black MSM, PrEP users and non-users did not
differ in depressive symptoms [60]. However, when considered as a part of syndemic
psychosocial conditions, including substance use, intimate partner violence, and depression,
greater syndemic conditions were associated with a greater likelihood of PrEP use [60].
Similarly, in another cross-sectional survey of 293 Black MSM, depression alone was not
associated with PrEP use, while a syndemic of two or more symptoms including depression,
alcohol consumption, illicit drug use, and transactional sex was associated with a lower
likelihood of PrEP use [37]. In contrast, a cross-sectional study conducted with 151 Latino
MSM in San Diego, CA found that a psychosocial syndemic of depression, binge drinking,
marijuana use, illicit polysubstance use, and/or childhood sexual abuse was not associated
with PrEP use [42].
Finally, a cross-sectional survey of 9697 PrEP users found that those who used PrEP
in an event-driven non-daily fashion were more likely to have depressive symptoms
compared with those who used PrEP daily [57].
4.3. PrEP Adherence and Retention
A total of 17 articles were included in the review that evaluated depression and outcomes of PrEP adherence and efficacy (see Table 4). Findings related to depressive symptoms
and PrEP adherence and discontinuation were mixed, with some studies identifying no association, while others showed poorer adherence and higher rates of PrEP discontinuation.
Adherence. A total of 12 studies examined associations between depression and PrEP
adherence. Six of these studies found that depressive symptoms were unrelated to adherence. This lack of relationship was shown in a cross-sectional survey of 31 cisgender males
and TGW in Philadelphia, PA [63]; a longitudinal analysis of 280 predominantly male PrEP
users in Miami, Florida (FL), San Francisco, CA, and Washington DC [64]; a longitudinal
analysis of 557 PrEP users from Miami, FL, San Francisco, CA, and Washington DC [65]; a
non-randomized open-label PrEP study of 226 MSM in Los Angeles, CA [55]; a randomized
control trial with 394 MSM and TGW in southern CA [66]; and a randomized control trial
conducted in New York City among 176 MSM [67].

Int. J. Environ. Res. Public Health 2021, 18, 11431

13 of 28

Table 4. Depression and PrEP Adherence and Retention.
Authors & Year

Location(s)

Sample Demographics

Design

Depression Measure

Depression Related Findings

San Diego, CA

151 Latino MSM;
Mean age: 24.

Cross-sectional survey

PHQ-8
10+ screened positive

A psychosocial syndemic (depression,
binge drinking, marijuana use, illicit
polysubstance use, childhood sexual
abuse) was associated with lowered
self-reported adherence.

Southern California

2995 PrEP candidates;
96.6% male;
60% racial/ethnic minorities;
50% < 35 years old.

Retrospective chart
review

Diagnostic codes

Depression was not associated with
PrEP persistence according to medical
and pharmacy records.

Colson, Franks, Wu et al.
2020 [68]

Harlem, NY

204 Black MSM (95.1%) and
TGW (4.9%) newly enrolled
on PrEP, 20.6% Latino;
Median age: 31.

Randomized control trial

CES-D
(16+ screened positive)

Gandhi, Murnane,
Bacchetti et al. 2017 [64]

Miami, Fl; San Francisco,
CA; Washington DC

280 PrEP users; 99% male,
78% White; Mean age: 34.

Longitudinal

PHQ-2
(dichotomous screening)

Southern California

394 MSM and TGW,
99% male; 76% White;
30% Hispanic;
Median age: 33.

Randomized control trial

PHQ-9
(continuous)

Baseline PHQ-9 scores were not
associated with adherence
according to DBS drug concentration.

Boston, MA

663 PrEP users; 96% male,
3% transgender women;
73% non-Hispanic White;
Median age: 32.6.

Retrospective chart
review

Medical problems list and
diagnostic codes

PrEP discontinuations were more likely
to occur in those who had multiple
mental health disorders (includes
anxiety, depression, substance use,
PTSD, bipolar, schizophrenia, and
attention deficit disorder).

Qualitative interviews

Qualitative focus

Participants indicated it was difficult to
keep track of medications when having
mental health problems.

Longitudinal

PHQ-2
(2+ screened positive)

Depression was not associated with
PrEP adherence.

Blashill, Brady,
Rooney et al. 2020 [42]

Bruxvoort, Schumacher,
Towner et al. 2021 [52]

Hoenigl, Jain, Moore 2018
[66]

Krakower, Maloney,
Powell et al. 2019 [71]

Laborde, Kinley,
Spinelli et al. 2020 [50]

San Francisco, CA

Liu, Cohen,
Vittinghoff et al. 2016 [65]

Miami, Fl; San Francisco,
CA; Washington DC

25 current or former PrEP
users; 60% MSM, 20% TGW
who have sex with men;
32% Black; 28% Hispanic;
Ages 18–57.
557 PrEP users; 48% White,
34% Latino; 98% MSM;
Mean age: 35.

Those who reported depressive
symptoms at baselines were less likely to
be adherent according to self-report and
dried blood spot (DBS) drug
concentration.
Depressive symptoms were not
associated with PrEP adherence
according to DBS drug concentration.
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Table 4. Cont.
Authors & Year
Mannheimer,
Hirsch-Moverman,
Franks et al. 2019 [67]

Location(s)

New York City, NY

Sample Demographics
176 MSM; 59% non-Hispanic
Black; 25% Hispanic;
Median age: 31.

Ogunbajo, Storholm,
Ober et al. 2021 [48]

Southern California

30 TGW; 33.3% Black/African
American;
53% Hispanic/Latina/Latinx;
46% straight
/heterosexual;
Mean age 29.8.

Pasipanodya, Jain,
Sun et al. 2018 [69]

Southern California

181 MSM; 81% White;
Mean age 34.98.

Scott, Spinelli,
Vittinghoff et al. 2019 [72]

San Francisco

Serota, Rosenberg,
Sullivan et al. 2020 [54]

Atlanta, GA

Spinelli, Laborde,
Kinley et al. 2020 [70]

San Francisco, CA

Wheeler, Fields,
Beauchamp et al. 2019
[55]

Los Angeles, CA;
Washington DC; Chapel
Hill, NC.

Young, Lalley-Chareczko,
Clark et al. 2020 [63]

Philadelphia, PA

Zucker, Carnevale,
Richards et al. 2019 [73]

Manhattan, NY

348 PrEP patients; 84% male;
39% White; 27% Latino;
Median age: 35.
298 non-Hispanic Black
cis-gender MSM; 73% gay;
62% ages 18–21.
8 individuals; 63% MSM,
38% TGW who have sex with
men; 38% White, 25% African
American; 25% Latinx;
38% ages < 25,
38% ages 40–64.
226 MSM; 86% Black;
73% Gay; Median age: 26
31 PrEP users; 87% male,
13% TGW; 74% African
American; 16% Hispanic;
Mean age: 21.7.
696 PrEP users, 93% male at
birth; 23% African American;
45.7% Hispanic;
54% age < 30.

Design

Depression Measure

Randomized control trial

CES-D
(16+ screened positive)

Mixed methods:
cross-sectional survey
and qualitative interviews

Qualitative focus

Longitudinal

PHQ
(categorical: 0–4, 5–9, 10–14)

Retrospective chart
review

Clinical diagnosis

Depression was not associated with
discontinuations in PrEP use.

Prospective observational
cohort study

PHQ-8
(10+ screened positive)

Depressive symptoms were not
associated with PrEP discontinuations.

Qualitative interviews

Qualitative focus

One participant noted depression and its
intersection with substance use as a
major barrier to adherence.

Non-randomized
open-label PrEP study

CESD-10
(10+ screened positive)

Depressive symptoms were not related
to PrEP adherence according to DBS
drug concentration.

Cross-sectional survey

PHQ-9
(10+ screened positive)

Depressive symptoms were not
associated with adherence according to
urine drug concentration.

Retrospective chart
review

PHQ-9
(5+ screened positive)

Depressive symptoms were not
associated with retention.

Note: PTSD = Post traumatic stress disorder.

Depression Related Findings
Depressive symptoms were not
associated with adherence measured
through self-report, pill counts, and DBS
drug concentration.
Mental health concerns, including
depression and anxiety, decreased
motivation to take PrEP, making it less of
a priority and making adherence
difficult. For some, however, PrEP
adherence was a coping mechanism.
Individuals with worse self-reported
adherence were more likely to have
depressive symptoms.
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In contrast, three studies found that depression was associated with poor adherence.
In a randomized control trial of 204 Black MSM and TGW in Harlem, NY, those who
reported depression at baseline were less likely to be adherent to PrEP [68]. As a part
of the TAPIR longitudinal study with 181 MSM in southern CA, those with the poorest
adherence were more likely to have depression compared with those with the best adherence [69]. Finally, one cross-sectional study with 151 Latino MSM examined a psychosocial
syndemic, including depression, binge drinking, marijuana use, illicit polysubstance use,
and childhood sexual abuse, which was associated with lower adherence. However, the
analyses did not differentiate between those with depression and those with other mental
health conditions [42].
Three qualitative studies found that depression hindered PrEP adherence. In a study
conducted in San Francisco, CA, one participant identified that depression was a barrier
to PrEP adherence, noting the link between depression and substance use as a particular
challenge. [70]. Another study conducted in San Francisco with 25 PrEP users found that
mental health problems were associated with adherence difficulties, although participants
did not indicate what specific symptoms they experienced [50]. Finally, in a study of
30 TGW in southern CA, participants indicated that mental health conditions, including
depression, decreased their motivation to take PrEP. PrEP adherence was a lower priority
compared to mental health symptoms. Of note, some participants indicated that taking their
PrEP on schedule was a way for them to positively cope with mental health symptoms [48].
Retention. Five studies examined PrEP discontinuation, four of which found no relationship between depression and PrEP discontinuation. In a prospective observational
cohort study of 298 non-Hispanic Black cisgender MSM in Atlanta, GA, baseline moderate to severe depressive symptoms were not associated with PrEP discontinuation [54].
Likewise, a retrospective chart review of 696 PrEP users in Manhattan, NY found that
depressive symptoms were not correlated with PrEP retention [73]. A retrospective chart
review of 348 PREP users at San Francisco Department of Health primary care clinics
found that a clinical diagnosis of depression noted in a patient’s chart was not associated
with PrEP discontinuation [72]. Similarly, in a retrospective chart review of 2995 PrEP
candidates in southern CA, diagnostic codes for depression were not associated with PrEP
persistence as measured by medical or pharmacy records [52]. In contrast, in a retrospective
chart review of 663 PrEP users at a community health center in Boston, Massachusetts
(MA), those with multiple mental health medical problem lists or diagnostic codes were
more likely to discontinue PrEP [71]. Importantly, this study examined anxiety, depression,
substance use, PTSD, bipolar disorder, schizophrenia, and attention deficit disorder, and
did not include analyses for individual disorders [71].
5. Anxiety
A total of 10 studies were identified that examined the impact of anxiety on various
PrEP stages (see Table 5).
5.1. PrEP Awareness
Two studies were identified that examined anxiety and PrEP awareness, PrEP interest,
and willingness to take PrEP. In a cross-sectional sample of 374 young, black MSM in
Nashville, TN and Buffalo, NY, anxiety was not associated with PrEP awareness, willingness to use PrEP, or actual PrEP use [36]. Likewise, in a cross-sectional sample of
52 cisgender women and TGW in East Harlem and the Bronx, NY, anxiety was not associated with PrEP interest [40].
One study found a relationship between anxiety and perceptions of LAI-PrEP. Twentyeight participants, predominantly MSM of color, were recruited from a study examining
long-acting PrEP injections. They qualitatively reported anxiety related to needles and
expected pain from the injection. However, this anxiety decreased across time, and was not
directly related to actual felt pain [74].
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5.2. PrEP Uptake
PrEP Access. One qualitative study using a focus groups of 37 predominantly transgender individuals in southern CA identified mental health concerns, including anxiety, to
be a barrier to PrEP care access. Participants reported these mental health concerns making
it difficult to access both PrEP care and other important health care services [49].
Linking to PrEP Care. One cross-sectional sample of 52 cisgender women and TGW in
East Harlem and the Bronx, NY found that anxiety was not associated with acceptance of a
PrEP appointment.
PrEP Initiation. One large national US cohort study, enrolling 6283 cisgender men and
transgender individuals who have sex with men demonstrated that anxiety symptoms
were not associated with self-reported individual prior or current use of PrEP [59].
5.3. PrEP Adherence and Retention
Adherence. Two studies found that anxiety is associated with poor PrEP adherence. In
a cross-sectional survey of 31 MSM and TGW in Philadelphia, PA, greater anxiety symptoms were associated with poorer PrEP adherence, as measured through urine tenofovir
concentration testing [63]. However, there was no association between anxious symptoms
and adherence to medical visits [63]. Similarly, qualitative findings from a study involving
30 TGW in southern CA revealed reports that mental health conditions including anxiety
decreased individuals’ motivation to take PrEP, making adherence difficult [48]. Importantly, however, some participants indicated that taking PrEP was a way in which they
coped with mental health conditions [48].
Retention. Three retrospective chart reviews have examined anxiety and PrEP discontinuations with somewhat mixed findings. In one large study of 2995 PrEP candidates
receiving care in southern CA, clinical mental health diagnoses including anxiety and
depression were not associated with PrEP maintenance [52]. Likewise, a retrospective
chart review of 348 PrEP patients receiving care in San Francisco, CA indicated that clinical
diagnoses of anxiety were not associated with PrEP discontinuation [72]. In contrast, a
study of 663 PrEP users in Boston, MA showed that those with multiple mental health
disorders indicated on medical charts, including anxiety, depression, substance use, PTSD,
dipolar disorder, schizophrenia, and attention deficit disorder, were more likely to discontinue PrEP [71]. However, analyses did not examine the effect of anxiety specifically on
PrEP discontinuation.
5.4. Effects of PrEP Use on Anxiety
Twelve studies examined the effects of taking PrEP on anxiety; these are detailed
in Table 6. Ten of the reviewed qualitative studies with samples sizes ranging from 10
to 89 suggest that positive perceptions of PrEP may be associated with reduced anxiety.
The studies primarily examined perceptions of men who identified as gay, bisexual, or
other MSM. However, one included men on PrEP without defining sexual identity or
activity [75]. In addition, one study included cisgender women and TGW; however, the
vast majority of the sample (93%) was cisgender men [76]. Participants reported a reduction
in anxiety generally [77,78], sex-related anxiety [75], HIV-related anxiety [76,79–82], and
anxiety related to partner dishonesty [82]. Participants described PrEP as providing “peace
of mind” [75,78,82]. Participants also identified PrEP as a possible component of couple’s
sexual agreements, in order to reduce sexual anxiety [83]. Moreover, a reduction in anxiety
was associated with increased feelings of control [80], responsibility [76], and enhanced
sexual wellbeing [75,79–81]. Indeed, in one study, participants identified reduced anxiety
as a primary motivator for willingness to take PrEP [84].
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Table 5. Effects of Anxiety across the PrEP Care Cascade.
Location(s)

Sample Demographics

Design

PrEP Stage

Anxiety Measure

Anxiety Related
Findings

Blackstock, Platt,
Golub et al. 2021 [34]

East Harlem, NY; Bronx,
NY

52 women, 11.5% TGW;
34.6% non-Latina Black;
51.9% Latina
/Hispanic, 42.3% LGB;
mean age: 45.

Pilot test

Awareness, initiation

GAD-2
(dichotomous screening)

Anxiety did not predict
PrEP interest or
appointment acceptance.

Liu, Brown,
Przybyla et al. 2021 [40]

Nashville, TN; Buffalo,
NY

374 MSM, 60.2% Black;
77% gay; median age: 26.

Cross-sectional survey

Awareness, initiation

GAD-7
categorical (0–4, 5–9,
10–14, 15–21)

Meyers, Rodriguez,
Brill et al. 2017 [74]

New York City, NY;
Philadelphia, PA

28 individuals receiving
long-acting injectable
cabotegravir; 60% MSM of
color; 14% Latino;
mean age: 31.

Mixed methods:
cross-sectional survey
and qualitative
interviews

Uptake

Qualitative focus

Watson, Pasipanodya,
Savin et al. 2020 [49]

San Diego, CA; Los
Angeles, CA

37 individuals; 48% TGW,
27% trans men; 41% White,
non-Hispanic; 16% Latinx
/Hispanic.

Qualitative focus groups

Access

Qualitative focus

Retrospective chart
review

Adherence and
retention

Diagnostic codes

Anxiety was not
associated with PrEP
referral or persistence.

Cross-sectional survey

Initiation

PHQ-4
(dichotomous screening)

Anxiety was not
associated with prior or
current PrEP use.

Authors & Year

Bruxvoort, Schumacher,
Towner et al. 2021 [52]

Southern California

Carneiro, Westmoreland,
Patel, and Grov 2020 [59]

United States

2995 PrEP candidates;
96.6% male;
60% racial/ethnic minorities;
50% < 35 years old.
6283 individuals; 98% cis
men; 52% White;
33% 30–39 years old

Anxiety was not
associated with PrEP
awareness, willingness
to use, or use.
Participants reported
anxiety related to
injections, which
decreased over time and
was not correlated with
pain. Two forms of
anxiety were present
related to needles and
expected pain.
Mental health concerns,
including depression
and anxiety, made it
difficult to access PrEP
care as well as other
services.
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Table 5. Cont.
Authors & Year

Ogunbajo, Storholm,
Ober et al. 2021 [48]

Young,
Lalley-Chareczko,
Clark et al. 2020 [63]
Scott, Spinelli,
Vittinghoff et al. 2019
[72]

Krakower, Maloney,
Powell et al. 2019 [71]

Location(s)

Sample Demographics

Design

PrEP Stage

Anxiety Measure

Anxiety Related
Findings

Mixed methods:
cross-sectional survey
and qualitative
interviews

Adherence and
retention

Qualitative focus

Mental health concerns,
including depression
and anxiety, decreased
motivation to take PrEP,
making it less of a
priority and making
adherence difficult. For
some, however, PrEP
adherence was a coping
mechanism.

GAD-7
(10+ screened positive)

Anxiety was associated
with lower adherence
according to urine drug
concentration.

Southern California

30 TGW;
33.3% Black/African
American; 53% Hispanic/Latina/Latinx;
46% straight
/heterosexual;
mean age 29.8.

Philadelphia, PA

31 PrEP users; 87% male,
13% transgender women;
74% African American;
16% Hispanic;
mean age: 21.7.

Cross-sectional survey

Adherence and
retention

San Francisco

348 PrEP patients; 84% male;
39% White; 27% Latino;
median age: 35.

Retrospective chart
review

Adherence and
retention

Diagnostic codes

Boston, MA

663 PrEP users; 96% male,
3% transgender women;
73% non-Hispanic White;
median age: 32.6.

Retrospective chart
review

Adherence and
retention

Medical problems list
and diagnostic codes

Note: GAD = Generalized Anxiety Disorder scale.

Anxiety was not
associated with
discontinuations in PrEP
use.
PrEP discontinuations
were more likely to occur
in those who had
multiple mental health
disorders (includes
anxiety, depression,
substance use, PTSD,
bipolar, schizophrenia,
and attention deficit
disorder).
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Table 6. Effects of PrEP Use on Anxiety.
Authors & Year

Location(s)

Sample Demographics
25 gay or bisexual men in HIV
serodiscordant relationships;
40% Black/African American;
32% Hispanic/Latino;
76% gay/homosexual, 24% bisexual.
10 MSM currently or formerly on PrEP;
75% Black; 95% non-Hispanic/Latino;
mean Age: 30.2.

Design

Anxiety Measure

Anxiety Related Findings

Mixed methods

Qualitative focus

Having less anxiety when having sex with an
HIV-positive partner was one of three reasons
participants indicated for willingness to take
PrEP.

Qualitative interviews

Qualitative focus

PrEP use reduced feelings of anxiety and
stress.

Brooks, Landovitz, Kaplan
et al. 2012 [84]

Los Angeles, CA

Devarajan, Sales, Hunt,
Comeau 2020 [77]

Atlanta, GA

Hammack, Toolis,
Wilson et al. 2019 [79]

New York City, NY; San
Francisco, CA; Tuscon, AZ;
Austin, TX

89 gay or bisexual men; 23.6% White;
24.7% Latino/Hispanic; 78.6% gay;
ages 18–59.

Qualitative interviews

Qualitative focus

Hojilla, Koester, Cohen et al.
2016 [75]

San Francisco, CA; Miami,
FL; Washington DC

26 men on PrEP; 62% White;
27% Hispanic.

Qualitative analysis of
counseling notes

Qualitative focus

Mitchell, Lee, Woodyatt et al.
2016 [83]

Atlanta, GA; Detroit, MI

19 male couples, most were non-Hispanic
and/or White; 28% of couples were
mixed race. Specific demographics are
unavailable; mean age: 33.

Qualitative interviews

Qualitative focus

Moeller, Seehuus, Wahl, and
Gratch 2020 [62]

United States

2406 MSM; 55% White; 18.6% Latino;
78.6% gay; mean age: 34.

Cross-sectional survey

GAD-7
categorical (0–4, 5–9,
10–14, 15+)

Mutchler, McDavitt, Ghani
et al. 2015 [78]

Los Angeles, CA

24 friend pairs; 83% male; 87.5% Black;
14.6% Latino; 68.8% gay; mean age: 22.1.

Qualitative interviews

Qualitative focus

PrEP improved sexual culture, making sex
more comfortable and enjoyable, and
reducing anxiety, particularly amongst
younger participants. PrEP alleviated anxiety,
removing HIV-related worry.
PrEP alleviated anxiety related to sex and
HIV, providing “peace of mind” and
alleviating anxiety for both participants and
their partners. As a result, some participants
explored sexual roles which they otherwise
would have not been comfortable with.
Some participants reported that PrEP could
be a part of couple’s agreements in order to
reduce sexual anxiety and risk, to keep the
couple safe.
PrEP users reported lowest levels of anxiety
compared with non-PrEP-using participants.
Among those on PrEP, internalized
homophobia, but not number of condomless
anal intercourse partners was associated with
greater anxiety. In contrast, for those not on
PrEP, greater number of CAI partners and
internalized homophobia were associated
with higher anxiety (r square = 0.06).
Participants described PrEP as a backup
option which could provide peace of mind
and reduce anxiety if other preventative
methods failed.
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Table 6. Cont.
Authors & Year

Location(s)

Sample Demographics

Design

Anxiety Measure

Quinn, Christenson, Sawkin
et al. 2020 [80]

Milwaukee, WI; Minneapolis,
MN; Detroit, MI; and Kansas
City, MO

36 Black MSM current/past PrEP users;
69% gay; mean age: 26.

Qualitative focus groups

Qualitative focus

Storholm, Volk, Marcus et al.
2017 [81]

San Francisco, CA

30 MSM PrEP users; 40% White;
23% Latino; mean age: 27.5.

Qualitative interviews

Qualitative focus

Whitfield, Jones, Wachman
et al. 2021 [85]

United States

1071 cis MSM PrEP users; 70% White;
11% Latino; 38.7% ages 25–34.

Longitudinal

Sexual anxiety MSSCQ
subscale
(continuous)

Yang, Krishnan, Kelley et al.
2020 [82]

Baltimore, MD

18 MSM PrEP users; 83% non-Hispanic
Black/African American.

Qualitative interviews

Qualitative focus

Zapata, Petroll, de St. Aubin,
and Quinn 2020 [76]

Milwaukee, WI

20 PrEP patients; 93% cis male;
60% White; 20% Hispanic; 85% gay;
mean age: 33.

Qualitative interviews

Qualitative focus

Anxiety Related Findings
PrEP reduced sexual and HIV-related anxiety,
including relieving anxieties related to having
sex, getting HIV tests, and potential fears of
acquiring HIV. This reduced anxiety created
sexual freedom, increasing control and
autonomy regarding sexual health and
providing the opportunity to explore without
fears of HIV.
Individuals indicated PrEP enhanced their
sexual wellbeing, decreasing HIV related
anxiety, and increasing openness to HIV
positive partners.
Participants showed less sexual anxiety when
on PrEP compared to their sexual anxiety
before beginning PrEP.
Participants reported PrEP as providing
“peace of mind”, reducing anxiety related to
HIV or partner dishonesty.
PrEP helped alleviate HIV-related anxiety,
allowing individuals to feel they were being
responsible.
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Two quantitative studies yielded similar results [62,85]. In a large cross-sectional
study of 2406 MSM, PrEP users reported lower levels of anxiety symptoms compared with
non-PrEP-users [62]. Moreover, while a greater number of condomless anal sex partners
was associated with heightened anxiety symptoms in those not on PrEP, this relationship
was not present for those on PrEP, suggesting that PrEP use buffers the effect of number of
condomless anal sex partners on anxiety symptoms [62]. In a large longitudinal analysis of
1071 cisgender MSM, sexual anxiety decreased for individuals after initiating PrEP [85].
6. Discussion
This scoping review examined current peer-reviewed US-based studies exploring
associations among depression, anxiety, and the PrEP care continuum for SGM individuals
and others at high risk for HIV. Findings indicate that depression and anxiety have distinct
relationships with the PrEP care continuum. The majority of studies reviewed found that
depression was not associated with PrEP awareness or willingness to use PrEP. In fact,
most of those studies that did identify a relationship showed that depressive symptoms
were associated with a higher likelihood of being willing to use PrEP to prevent HIV.
Although depressive symptoms have been identified as barriers to PrEP care [49,50],
this review suggests that depressive symptoms alone do not stymie PrEP uptake [56,58].
Indeed, cross-sectional analyses have found depressive symptoms to be positively associated with PrEP use [33,61,62]. However, due to their cross-sectional nature, these studies
cannot make causal or temporal inferences. In addition, two studies found that depression
alone was not associated with PrEP use, although it was when depression was part of
syndemic conditions [37,60]. The salience of syndemic risks and health conditions among
SGM has been highlighted previously, with prior research showing that SGM individuals
are disproportionately impacted by intersecting psychosocial risks (e.g., substance use,
depression, trauma) that together create challenging dynamics for physical health [86–88].
Current findings echo previous calls for novel assessment and intervention strategies that
target multiple co-occurring risks among SGM populations [86]. In other words, clinicians
and PrEP providers should be careful to not consider depression in isolation when discussing/recommending PrEP—but rather, should pay close attention to a constellation of
risks (e.g., depressive symptoms, substance use, social isolation) that, taken together, may
create significant barriers to PrEP initiation and adherence.
The majority of the studies that examined depression and PrEP focused on the role
of depression in PrEP adherence, with largely mixed findings. Although the majority of
identified articles found no relationship between depression and adherence, several studies
showed that depression was negatively associated with PrEP adherence [42,68,69]. One
study examining data from the iPrEX open label extension, which is not included in the
present scoping review due to its global nature and aggregated findings, found that moderate levels of depressive symptoms were associated with the highest level of adherence,
compared with severe and mild levels of depressive symptoms. Individuals with severe
symptoms of depression had the worst adherence of all groups [89]. Thus, it is possible that
depressive symptoms have a non-linear relationship with adherence, which may explain
previous mixed findings on the relationship between depression and adherence.
Compared with depression, there has been relatively less research on anxiety and the
PrEP care continuum. Overall, the literature reviewed here suggest that anxiety has limited
impact on PrEP awareness, willingness to use, or actual use among SGM individuals.
However, anxiety symptoms were identified as a potential barrier to care in qualitative
studies. In addition, while some studies found that anxiety was associated with poorer
adherence, it was not associated with PrEP discontinuation. The relationship between
anxiety and PrEP is likely a bidirectional one. A sizeable majority of the studies examining
PrEP and anxiety examined the effect PrEP had on anxiety through qualitative methods,
with participants indicating the ways in which PrEP brought them peace of mind. This
peace of mind may provide a sense of sexual freedom, enabling individuals to have sex
without HIV-related anxiety. This is related to the concept of risk compensation, which,
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when applied to PrEP, posits that use of PrEP would reduce an individual’s perceived
risks, which enables them to engage in other sexual risk behaviors [90]. Although risk
compensation has been used as an argument against PrEP prescription, this view has been
critiqued [90]. However, risk compensation may explain the reductions in anxiety related
to condomless anal sex for MSM taking PrEP compared with those not taking PrEP.
6.1. Current Gaps and Future Directions
A number of gaps in existing research on the role of depression and anxiety in the
PrEP care continuum were identified through the current scoping review. First, more clarity
is needed on the relationship between depression and PrEP use, including longitudinal
studies that examine these relationships over time in order to assess potential bidirectional
temporal changes. Second, measures used to examine depression in PrEP-related research
should be expanded. As previously discussed, Mehrotra and colleagues uncovered a
non-linear relationship between depression and adherence by employing a categorical measure [89]. The vast majority of the current research has used dichotomous categorizations
for depression, which do not allow for this nuanced understanding. Therefore, future research should consider expanding measures used to evaluate depressive symptoms beyond
brief screening measures and consider multi-categorical analyses in addition to traditional
cut-score methods. For example, the Center for Epidemiologic Studies Depression (CESD)
scale yields scores ranging from 0 to 60, with a traditional screening cut-score of 16 [91].
However, analyses with multiple categories (e.g., mild, moderate, severe depression) may
reveal important differences. Finally, future research should examine depression and the
PrEP care cascade for TGW specifically. Although many of the current studies included
TGW, the samples of TGW tended to be so small as to prohibit both cross-comparison with
MSM and within-group analyses. Because rates of depression and HIV are so high among
TGW, studies that focus exclusively on this population are urgently needed.
In terms of anxiety and the PrEP care continuum, this review revealed that when
compared to depression, there is a dearth of research on the impact of anxiety on the
PrEP care continuum. In addition, most studies that were reviewed were based in large
metropolitan areas on the East or West coast. This highlights a current geographic gap—
SGM in the southern US and rural areas are disproportionately impacted by the HIV
epidemic, and these areas are key targets in the new federal Ending the HIV Epidemic
plan [92]. However, there is limited research on anxiety and PrEP emerging from these
key geographic areas. For example, the two studies that were reviewed and found no
relationship between anxiety and PrEP awareness as well as willingness to use PrEP
were both conducted in NY [36,40]. Given different sociocultural environments, it is
possible that geographic differences could affect the role of anxiety in PrEP perceptions
or willingness to seek and use PrEP. The ‘Deep South’, in particular, has become the
epicenter of the US HIV epidemic and now has higher HIV rates and greater HIV-associated
morbidity and mortality than any other region [92,93]. Multiple drivers of these regional
HIV disparities exist, including systemic racism, homophobia, and transphobia; sociocultural factors (e.g., socio-religious norms, stigmatized sexuality); healthcare disparities;
structural barriers (e.g., housing, transportation); and policy-related factors (e.g., lack of
Medicaid expansion) [92,94]. Taken together, these may certainly have an effect on anxiety
of SGM and their desires or attempts to access PrEP. Expanding the geographic and social
contexts of this research is important across the care cascade. In addition, more research
is needed to examine the effects of PrEP on anxiety within populations other than MSM.
Similar to depression, future research is also needed to examine longitudinal changes in
anxiety symptoms as a result of PrEP use.
Finally, researchers should consider multiple ways of operationalizing anxiety. Most of
the studies identified used dichotomous classifications for anxiety or qualitative reports of
anxiety. Although these are useful, this method of analysis does not allow for a distinction
between mild, moderate, or severe anxiety symptoms. Only one identified study used
this method [40]. It may be that symptom severity influences outcomes. Prior research
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on Chronic Hepatitis C treatment adherence has supported the application of the Yerkes–
Dodson law related to anxiety and treatment adherence, such that moderate levels of
anxiety were related to best adherence [95]. Similarly, it may be that a certain level of
anxiety is adaptive, while high levels of anxiety are harmful in PrEP adherence. More
research is needed to understand this complex relationship.
Given the importance of anxiety and depression on the PrEP care continuum, healthcare providers prescribing PrEP should be aware of mental health considerations and be
ready to implement screening protocols and provide referrals for mental health services
for those with symptoms of anxiety and depression [17]. Alternatively, a self-screening
for depression and substance use can be implemented, as done at a hospital in Toronto,
Canada, with this method found to be acceptable and feasible [96]. By including such
screenings, practitioners can link patients to mental healthcare providers, thus meeting
the physical and mental healthcare needs of individuals. In addition, adherence-related
interventions are likely appropriate for those experiencing anxiety and depression. One
such intervention is the “Life-Steps” approach, which uses cognitive-behavioral techniques
and motivational interviewing to support creating dosing schedules and problem solving for potential adherence barriers [97,98]. Advances in mobile technology also allow
for mHealth interventions, such as text reminders, which are effective in improving adherence [99]. Despite the potential challenges related to mental health disorders, some
symptoms may also help to motivate PrEP uptake. For instance, in some studies, moderate
depressive symptoms were associated with greater interest; similarly, a desire to reduce
anxiety surrounding condomless sex can also be a motivator for PrEP uptake.
6.2. Limitations
This scoping review has several limitations. First, the scope of the review was limited
to US-based research. Although this was purposeful due to the varying nature of the
HIV epidemics and presentation of depression and anxiety across cultural and geographic
settings, this limits the generalizability of the summarized findings. Important findings
related to anxiety or depression and PrEP may have been overlooked due to this decision.
Second, the review focused on studies that included those on PrEP or who were PrEP
candidates. This eliminated studies that focused on the perceptions of healthcare and
mental health providers, which could provide insights into whether an individual is likely
to receive a prescription, a key component to the PrEP care continuum. Third, although
narrative descriptions of studies included informal analyses of article quality (e.g., study
design, sample size), no formal quality assessment was conducted. Finally, many of the
studies reviewed utilized cross-sectional data, prohibiting an understanding of potential
causal relationships between PrEP and mental health.
7. Conclusions
The high prevalence of depression, anxiety, and HIV among SGM populations makes
it important to consider the relationship between these mental health disorders and the
PrEP care continuum. The present scoping review reveals that while anxiety and depression may not have major impacts on PrEP awareness or PrEP willingness, they can be
barriers to access to care and can impact an individual’s adherence to PrEP. Moreover, the
relationship between PrEP and these mental health conditions appears to be bidirectional.
In particular, PrEP use reduces feelings of anxiety. Practitioners should implement mental
health screenings to ensure PrEP candidates and users with mental health conditions are
linked to appropriate care.
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